<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385267</url>
  </required_header>
  <id_info>
    <org_study_id>08074</org_study_id>
    <nct_id>NCT01385267</nct_id>
  </id_info>
  <brief_title>Fetal Lung Maturation in Twin Gestations</brief_title>
  <official_title>Fetal Lung Maturation in Twin Gestations Based on Birth Order and Weight Discordance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriHealth Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
      To evaluate discordance in lung maturity in diamniotic twins based on birth order, sex and&#xD;
      body weight. If we find discordance in fetal lung maturity in twin gestations this will&#xD;
      change current practice of sampling only one amniotic sac for evaluation of fetal lung&#xD;
      maturity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      To evaluate discordance in lung maturity in diamniotic twins based on birth order, sex and&#xD;
      body weight. If we find discordance in fetal lung maturity in twin gestations this will&#xD;
      change current practice of sampling only one amniotic sac for evaluation of fetal lung&#xD;
      maturity.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
      Lung maturation within twin pairs is weakly correlated based on presentation and estimated&#xD;
      fetal weight.&#xD;
&#xD;
      Research Methods:&#xD;
&#xD;
      This study will be prospective cohort study of women with twin diamniotic intrauterine&#xD;
      gestations who will be delivered at a Good Samaritan or Bethesda North Hospital. Patients&#xD;
      will be counseled and informed consent for participation in the study will be obtained prior&#xD;
      to enrollment in study.&#xD;
&#xD;
      At the time of Cesarean delivery or in the event of amniocenteses for FLM, a sample of&#xD;
      amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac&#xD;
      will be aspirated by the obstetrician and sent to the laboratory for determination of fetal&#xD;
      lung maturity index and lamellar body count. Fetal lung maturity index and lamellar body&#xD;
      count will be correlated to see if there is an association between Twin A and Twin B.&#xD;
&#xD;
      Fetal Lung Maturity index and lamellar body count will be calculated and compared based on&#xD;
      fetal weight, sex, zigosity, and birth order. Demographic information, maternal obstetrical&#xD;
      and medical history, newborn/fetal data, indications for cesarean section and twin A and B&#xD;
      outcomes will be obtained through OB Traceview or patient chart.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Participants will include pregnant patients, greater than 24 completed weeks with diamniotic&#xD;
      twin gestations, at Good Samaritan and Bethesda North Hospitals. Patients will be scheduled&#xD;
      for a cesarean section by their primary MD prior to being approached for inclusion into the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>FLM Index</measure>
    <time_frame>3 years</time_frame>
    <description>FLM Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lamellar Body Counts</measure>
    <time_frame>3 years</time_frame>
    <description>Lamellar Body Counts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory Distress Syndrome</measure>
    <time_frame>3 years</time_frame>
    <description>Respiratory Distress Syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Tachypnea in newborns</measure>
    <time_frame>3 years</time_frame>
    <description>Transient Tachypnea in newborns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Death</measure>
    <time_frame>3 years</time_frame>
    <description>Neonatal Death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Discordance in Lung Maturity in Diamniotic Twins</condition>
  <arm_group>
    <arm_group_label>Diamniotic twin gestations</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>aspiration of amniotic fluid</intervention_name>
    <description>a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.</description>
    <arm_group_label>Diamniotic twin gestations</arm_group_label>
    <other_name>diamniotic twins</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each&#xD;
      amniotic sac will be aspirated by the obstetrician and sent to the laboratory for&#xD;
      determination of fetal lung maturity index and lamellar body count. Fetal lung maturity index&#xD;
      and lamellar body count will be correlated to see if there is an association between Twin A&#xD;
      and Twin B.&#xD;
&#xD;
      Fetal Lung Maturity index and lamellar body count will be calculated and compared based on&#xD;
      fetal weight, sex, zigosity, and birth order. Demographic information, maternal obstetrical&#xD;
      and medical history, newborn/fetal data, indications for cesarean section and twin A and B&#xD;
      outcomes will be obtained through OB Traceview or patient chart.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will include pregnant patients, greater than 24 completed weeks with&#xD;
        diamniotic twin gestations, at Good Samaritan and Bethesda North Hospitals. Patients will&#xD;
        be scheduled for a cesarean section by their primary MD prior to being approached for&#xD;
        inclusion into the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diamniotic twin gestations&#xD;
&#xD;
          -  Twenty-four completed weeks gestation with dating calculated by their sure last&#xD;
             menstrual period or utilizing a first trimester crown rump length ultrasound.&#xD;
&#xD;
          -  English Speaking&#xD;
&#xD;
          -  Scheduled cesarean section by patient's primary MD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Monoamniotic twins&#xD;
&#xD;
          -  Presence of gross blood in amniotic sample&#xD;
&#xD;
          -  Presence of meconium amniotic fluid&#xD;
&#xD;
          -  Known/diagnosed fetal or newborn anomaly&#xD;
&#xD;
          -  Twin to Twin Transfusion Syndrome (TTTS)&#xD;
&#xD;
          -  Vaginal delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna Lambers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TriHealth Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>December 27, 2018</last_update_submitted>
  <last_update_submitted_qc>December 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

